Cargando…
Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of ther...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342782/ https://www.ncbi.nlm.nih.gov/pubmed/37445475 http://dx.doi.org/10.3390/jcm12134440 |
_version_ | 1785072581653561344 |
---|---|
author | Gerov, Vladimir Gerova, Daniela Micheva, Ilina Nikolova, Miglena Mihaylova, Galya Galunska, Bistra |
author_facet | Gerov, Vladimir Gerova, Daniela Micheva, Ilina Nikolova, Miglena Mihaylova, Galya Galunska, Bistra |
author_sort | Gerov, Vladimir |
collection | PubMed |
description | Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of therapy, including autologous stem cell transplantation (ASCT). This study included 41 NDMM-patients and 33 controls. MBD was assessed by whole-body low-dose computed tomography. DKK-1 and sclerostin were assayed by commercial ELISA kits. At diagnosis, NDMM-patients revealed significantly higher DKK-1 and sclerostin values (p < 0.0001), showing dependence on disease stage (lowest in ISS-I and highest in ISS-III: p < 0.0012 and p < 0.025, respectively, for both proteins). Bone lesions revealed significant positive correlation with both DKK-1 (p < 0.05) and sclerostin (p < 0.0001). In the course of therapy, significant reduction, more prominent after ASCT, was observed for both parameters in each treatment point compared to the baseline (p < 0.0001). Markedly lower sclerostin (p < 0.01) and DKK-1 (p < 0.05) values were observed in patients with complete and very good partial response compared to those with partial response, stable, or progressive disease. Sclerostin and DKK-1 in NDMM patients reflect the MBD severity and the effect of therapy. Both proteins could represent a novel tool for better disease monitoring and effectiveness of therapy. |
format | Online Article Text |
id | pubmed-10342782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103427822023-07-14 Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma Gerov, Vladimir Gerova, Daniela Micheva, Ilina Nikolova, Miglena Mihaylova, Galya Galunska, Bistra J Clin Med Article Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of therapy, including autologous stem cell transplantation (ASCT). This study included 41 NDMM-patients and 33 controls. MBD was assessed by whole-body low-dose computed tomography. DKK-1 and sclerostin were assayed by commercial ELISA kits. At diagnosis, NDMM-patients revealed significantly higher DKK-1 and sclerostin values (p < 0.0001), showing dependence on disease stage (lowest in ISS-I and highest in ISS-III: p < 0.0012 and p < 0.025, respectively, for both proteins). Bone lesions revealed significant positive correlation with both DKK-1 (p < 0.05) and sclerostin (p < 0.0001). In the course of therapy, significant reduction, more prominent after ASCT, was observed for both parameters in each treatment point compared to the baseline (p < 0.0001). Markedly lower sclerostin (p < 0.01) and DKK-1 (p < 0.05) values were observed in patients with complete and very good partial response compared to those with partial response, stable, or progressive disease. Sclerostin and DKK-1 in NDMM patients reflect the MBD severity and the effect of therapy. Both proteins could represent a novel tool for better disease monitoring and effectiveness of therapy. MDPI 2023-07-01 /pmc/articles/PMC10342782/ /pubmed/37445475 http://dx.doi.org/10.3390/jcm12134440 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gerov, Vladimir Gerova, Daniela Micheva, Ilina Nikolova, Miglena Mihaylova, Galya Galunska, Bistra Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title | Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title_full | Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title_fullStr | Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title_full_unstemmed | Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title_short | Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma |
title_sort | dynamics of bone disease biomarkers dickkopf-1 and sclerostin in patients with multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342782/ https://www.ncbi.nlm.nih.gov/pubmed/37445475 http://dx.doi.org/10.3390/jcm12134440 |
work_keys_str_mv | AT gerovvladimir dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma AT gerovadaniela dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma AT michevailina dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma AT nikolovamiglena dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma AT mihaylovagalya dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma AT galunskabistra dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma |